OXFORD BIOMEDICA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 270 GBX | +3.85% |
|
+26.05% | +23.18% |
| Apr. 29 | FTSE 100 as investors look to Fed rate decision | AN |
| Apr. 29 | Transcript : Oxford Biomedica plc, Q4 2023 Earnings Call, Apr 29, 2024 |
| Sales 2023 | 89.54M 112M | Sales 2024 * | 130M 163M | Capitalization | 260M 326M |
|---|---|---|---|---|---|
| Net income 2023 | -157M -197M | Net income 2024 * | -40M -50.14M | EV / Sales 2023 | 2.38 x |
| Net cash position 2023 * | 49.23M 61.71M | Net cash position 2024 * | 12.97M 16.26M | EV / Sales 2024 * | 1.9 x |
| P/E ratio 2023 |
-1.35
x | P/E ratio 2024 * |
-6.46
x | Employees | 891 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.81% |
More Fundamentals
* Assessed data
More news
Latest transcript on Oxford Biomedica plc
More press releases
More news
| 1 day | +0.38% | ||
| 1 week | +18.33% | ||
| Current month | +26.58% | ||
| 1 month | +29.80% | ||
| 3 months | +39.79% | ||
| 6 months | +18.89% | ||
| Current year | +15.64% |
1 week
211.50
262.94
1 month
187.83262.94
Current year
167.00262.94
1 year
164.29474.50
3 years
164.291 678.00
5 years
164.291 678.00
10 years
95.501 678.00
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 23-03-26 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 17-08-28 |
| Chairman | 68 | 20-06-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 23-04-30 |
| Chairman | 68 | 20-06-23 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 16-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 271 | +4.23% | 54 611 |
| 24-04-29 | 260 | +13.79% | 641,647 |
| 24-04-26 | 228.5 | +3.86% | 298,641 |
| 24-04-25 | 220 | +0.69% | 221,132 |
| 24-04-24 | 218.5 | +1.63% | 275,918 |
Delayed Quote London S.E., April 30, 2024 at 03:42 am EDT
More quotes
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.6
GBP
Average target price
4.179
GBP
Spread / Average Target
+60.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.64% | 326M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.69% | 22.18B | |
| -16.67% | 21.2B | |
| -8.65% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- OXB Stock
